A Study of MEDI-575 in Patients with Advanced Solid Malignancies
Study identifier:D2840C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients with Advanced Solid Malignancies
Medical condition
Advanced solid malignancies
Phase
Phase 1
Healthy volunteers
No
Study drug
MEDI-575
Sex
All
Actual Enrollment
23
Study type
Interventional
Age
20 Years - 150 Years
Date
Study Start Date: 01 Mar 2010
Primary Completion Date: 01 Nov 2012
Study Completion Date: 01 Nov 2012
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2014 by MedImmune, LLC
Sponsors
MedImmune, LLC
Collaborators
MedImmune
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: MEDI-575 MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part |
